Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Journal: Journal for immunotherapy of cancer
Published: March 11, 2024
Unexpected heterogeneity in oropharyngeal squamous cell tumors.
Journal: Nature genetics
Published: April 04, 2023
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043.
Journal: Nature communications
Published: September 30, 2022
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Journal: Journal for immunotherapy of cancer
Published: July 15, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 20, 2022
A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience.
Journal: European journal of haematology
Published: March 18, 2022
NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter's Transformation and CLL/SLL.
Journal: Case reports in hematology
Published: June 07, 2021
Burkitt Lymphoma International Prognostic Index.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 27, 2021
Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience.
Journal: Journal of clinical apheresis
Published: November 13, 2020
Refractory acquired angioedema in chronic lymphocytic leukemia.
Journal: Leukemia & lymphoma
Published: August 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 27, 2020
Last Updated: 09/26/2026